Search
Erenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalErenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marke...
Stem bromelain
go.drugbank.com/drugs/DB12249ApprovedThe primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand name Nexobrid [FDA Label]. Bro...
Mebendazole
go.drugbank.com/drugs/DB00643ApprovedInvestigationalVet approvedA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]
Modafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalModafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing pe...
Edetic acid
go.drugbank.com/drugs/DB00974ApprovedInvestigationalVet approvedA chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Oxprenolol
go.drugbank.com/drugs/DB01580ApprovedWithdrawnA beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
Iomeprol
go.drugbank.com/drugs/DB11705ApprovedInvestigationalIomeprol is a tri-iodinated, non-ionic radiographic contrast agent for intraarterial or intravenous use. Iomeprol demonstrates low chemotoxicity, osmolality and viscosity and high water solubility. Iomeprol first appeared in the market i...
Clioquinol
go.drugbank.com/drugs/DB04815ApprovedVet approvedWithdrawnClioquinol was withdrawn in 1983 due to neurotoxicity.
Mixtures: CORTINOL D, BENTIXMesmulogene ancovacivec
go.drugbank.com/drugs/DB06584InvestigationalExpression of IL-2 augments the specific CTL response against MUC1 expressing cells. [L5191] … A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities
OPC-28326
go.drugbank.com/drugs/DB05461ExperimentalAt low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary